Tema Etfs LLC Sells 1,676 Shares of argenex SE $ARGX

Key Points

• Tema Etfs LLC has reduced its stake in argenex SE by 36.5%, now holding 2,922 shares worth approximately $1,729,000.
• Institutional investors own 60.32% of argenex, with recent increases in holdings by Rakuten Securities Inc. and Brooklyn Investment Group.
• Analysts have set a consensus price target of $763.47 for argenex, with many ratings upgraded to "buy" and "strong buy" in recent reports.

Tema Etfs LLC decreased its position in argenex SE (NASDAQ:ARGX - Free Report) by 36.5% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 2,922 shares of the company's stock after selling 1,676 shares during the period. Tema Etfs LLC's holdings in argenex were worth $1,729,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Dimensional Fund Advisors LP boosted its holdings in argenex by 21.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 24,929 shares of the company's stock valued at $15,332,000 after acquiring an additional 4,445 shares in the last quarter. Stifel Financial Corp boosted its holdings in shares of argenex by 6.8% during the 4th quarter. Stifel Financial Corp now owns 9,433 shares of the company's stock valued at $5,801,000 after buying an additional 601 shares in the last quarter. Voya Investment Management LLC boosted its holdings in shares of argenex by 47.8% during the 4th quarter. Voya Investment Management LLC now owns 14,170 shares of the company's stock valued at $8,715,000 after buying an additional 4,585 shares in the last quarter. Coldstream Capital Management Inc. bought a new stake in shares of argenex during the 4th quarter valued at $205,000. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of argenex by 0.9% during the 4th quarter. The Manufacturers Life Insurance Company now owns 62,113 shares of the company's stock valued at $38,199,000 after buying an additional 527 shares in the last quarter. Institutional investors own 60.32% of the company's stock.

argenex Trading Up 1.2%

NASDAQ:ARGX traded up $8.13 during mid-day trading on Monday, reaching $712.20. The company's stock had a trading volume of 353,562 shares, compared to its average volume of 379,007. argenex SE has a 12-month low of $510.05 and a 12-month high of $716.62. The firm's fifty day moving average price is $611.18 and its two-hundred day moving average price is $599.12. The stock has a market cap of $43.59 billion, a P/E ratio of 36.52, a PEG ratio of 0.81 and a beta of 0.41.

argenex (NASDAQ:ARGX - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $3.74 earnings per share for the quarter, topping analysts' consensus estimates of $2.84 by $0.90. argenex had a return on equity of 21.06% and a net margin of 40.98%.The business had revenue of $866.79 million during the quarter, compared to analyst estimates of $776.82 million. Analysts predict that argenex SE will post 3.13 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently commented on ARGX. Oppenheimer boosted their target price on shares of argenex from $704.00 to $708.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Baird R W upgraded shares of argenex from a "hold" rating to a "strong-buy" rating in a report on Tuesday, May 13th. Piper Sandler lifted their price target on argenex from $750.00 to $820.00 and gave the stock an "overweight" rating in a research report on Tuesday, August 26th. Wells Fargo & Company lifted their price target on argenex from $741.00 to $756.00 and gave the stock an "overweight" rating in a research report on Thursday, July 31st. Finally, Citigroup reaffirmed a "buy" rating on shares of argenex in a research report on Wednesday, May 21st. Two investment analysts have rated the stock with a Strong Buy rating and twenty have assigned a Buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $766.50.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.